Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyCommunity-Care sebelipase alfa Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Medical Benefit Medication Utilization Policy — sebelipase alfa (LAL deficiency) coverage criteria

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy defines medical benefit coverage criteria, authorization, quantity limits, and coding for sebelipase alfa for treatment of lysosomal acid lipase (LAL) deficiency for members under the payer's medical benefit.

    Policy Summary
    PayerCommunity-Care
    Policysebelipase alfa (LAL deficiency) coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2022
    Next Review DateN/A
    Key ActionObtain prior authorization with documentation confirming LAL deficiency and prescriber specialty or consultation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J2840HCPCS code for sebelipase alfa (1 mg)
    1 yearauthorization period if approved
    nonequantity limits
    ≥1 metric

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    continuation requires

    Coverage Criteria for Sebelipase Alfa

    Initial Therapy

    Covered when ALL of the following are met:

    Initial Approval - LAL deficiency: (i) Prescribed by, or in consultation with, an endocrinologist, genetic specialist, or provider specialized in metabolic disorders; (ii) Diagnosis of lysosomal acid lipase deficiency confirmed via documentation of deficient LAL enzyme activity or genetic testing; (iii) One of the following: (1) Rapidly progressive disease that presented within first six months of life, OR (2) Disease presented after first six months of life.

    Continuation Therapy

    Covered when ALL of the following are met:

    Continuation of Therapy - LAL deficiency: (i) Diagnosis of lysosomal acid lipase deficiency; (ii) Documentation of a positive clinical response from baseline, evidenced by at least one of the following: (1) Reduction in total cholesterol, LDL-C, triglycerides, ALT, or AST; (2) Increase in HDL-C; (3) Improvement in weight-for-age z-scores for patients exhibiting growth failure.

    The policy document does not list any explicit exclusions for coverage of sebelipase alfa for treatment of lysosomal acid lipase (LAL) deficiency. No specific patient populations, indications, or circumstances were identified in the source as excluded from consideration.

    The policy does not specify any conditions that are explicitly deemed not medically necessary. Coverage determinations are governed by the stated initial and continuation criteria rather than by a named list of noncovered clinical scenarios.

    Coding and Authorization Period

    Applicable HCPCS CodesHCPCS
    J2840Injection, sebelipase alfa, 1 mg
    Authorization period — 1 year
    Authorization periodIf approved, coverage is allowed for 1 year (subject to benefit changes).
    Required documentation related to approval periodA recorded patient weight is required for approval (authorization granted for up to 1 year).
    Renewal implicationContinuation requests should demonstrate required clinical response measures to support renewal beyond the initial authorization period.

    Provider Requirements and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Requests must include documentation confirming the diagnosis of lysosomal acid lipase (LAL) deficiency (see documentation requirements) and confirm the prescriber is an endocrinologist, genetic specialist, or provider specialized in metabolic disorders, or that such a specialist was consulted.

    • Prior authorization required for initiation and continuation of therapy
    • Prescriber specialty or documented consultation required
    Documentation Required

    Required Documentation

    Documentation must include confirmation of LAL enzyme deficiency by enzyme activity testing or genetic testing, clinical presentation details (including age at presentation and disease course), baseline laboratory values (lipid panel, ALT, AST), and patient weight.

    • Confirmatory testing: deficient LAL enzyme activity OR pathogenic variant on genetic testing

    Background

    Lysosomal acid lipase (LAL) deficiency is described in the policy context as a genetic metabolic disorder that requires confirmation by laboratory testing. A diagnosis for coverage purposes must be documented by either deficient LAL enzyme activity or genetic testing demonstrating LAL deficiency. Treatment with sebelipase alfa is managed under specialist care and continuation of therapy is assessed by objective clinical response measures such as changes in lipid levels, liver enzymes, or growth parameters.

    Definitions

    LAL deficiency diagnosis — confirmed diagnosis requires deficient LAL enzyme activity or genetic testing
    Confirmatory testing requiredDiagnosis must be confirmed via documentation of deficient LAL enzyme activity or genetic testing.
    Prescriber specialtyPrescribed by, or in consultation with, an endocrinologist, genetic specialist, or provider specialized in metabolic disorders.
    Role in continuationContinuation of therapy requires ongoing documentation of the diagnosis and evidence of clinical response from baseline.
    Policy Summary
    PayerCommunity-Care
    Policysebelipase alfa (LAL deficiency) coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2022
    Next Review DateN/A
    Key ActionObtain prior authorization with documentation confirming LAL deficiency and prescriber specialty or consultation.
    SourceLink
    On This Page
    Coverage Criteria for Sebelipase AlfaCoding and Authorization PeriodProvider Requirements and AuthorizationBackgroundDefinitions
  1. Baseline labs: total cholesterol, LDL-C, HDL-C, triglycerides, ALT, AST
  2. Weight (required for dosing/approval)
  3. Step Therapy

    Step Therapy

    There are no step therapy requirements specified for this therapy.

    Denial Risk

    Triggers for Denial

    Coverage may be denied if required documentation is missing or does not confirm LAL deficiency. Examples of triggers for denial include absence of confirmatory enzyme activity or genetic test results, missing prescriber specialty/consultation documentation, lack of baseline laboratory or weight data, or failure to demonstrate initial eligibility criteria.

    • Missing confirmatory testing for LAL deficiency
    • No documentation of prescriber specialty or specialist consultation
    • Absent baseline labs or weight
    • Failure to meet initial coverage criteria (e.g., insufficient clinical information on disease presentation)